Performance of 4 methods for screening of latent tuberculosis infection in patients with chronic inflammatory arthritis under TNFα inhibitors: a 24-month prospective study

Table 1 Demographic and clinical data of patients treated with TNFα inhibitors

Parameter	JIA (n = 20)	RA (n = 40)	AS (n = 35)	PsA (n = 7)	p value
Age (years)	14.2 ± 7.2^a	55.5 ± 9.3^c	42.8 ± 9.9^b	54.3 ± 6.7^c	0.001
Female sex	12 (60%)	36 (90%)	10 (28.5%)	3 (42.9%)	0.001
Length of disease (years)	5.6 ± 3.3^a	14.8 ± 8.2^b	12.5 ± 7.7^b	18.0 ± 7.9	0.001
Disease activity
BASDAI			1.76 ± 1.51
DAS28		2.86 ± 0.8
PASI				2.68 ± 4.12
Current medications
Concomitant
GC	1 (5%)	11 (27.5%)	0	0	0.001
Methotrexate	7 (35%)	17 (42.5%)	3 (8.6%)	5 (71.4%)	0.001
Leflunomide	7 (35%)	20 (50%)	0	1 (14.3%)	0.001
Sulfasalazine	0	0	4 (11.4%)	0	0.079
NSAIDs	2 (10%)	0	12 (34.3%)	0	0.001
CG	1 (5%)	11 (27.5%)	0	0	0.001
Cyclosporine	1 (5%)	0	0	0	0.267
Mesalazine	2 (10%)	0	0	0	0.07
Length of TNFi use to TNF inhibitorsα (years)	1.4 ± 1.1^a	2.4 ± 1.9^a	3.5 ± 1.6^b	3.9 ± 1.9^b	0.001
TNFα inhibitors					0.057
Adalimumab	5 (25%)	11 (27.5%)	7 (20%)	4 (57.2%)
Etanercept	9 (45%)	22 (55%)	14 (40%)	0
Infliximab	6 (30%)	7 (17.5%)	14 (40%)	3 (42.8%)

Student’s t-test, ANOVA; JIA, juvenile idiopathic arthritis; RA, rheumatoid arthritis; AS, ankylosing spondylitis; PsA, psoriatic arthritis; DAS-28, Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; PASI, Psoriasis Area Severity Index; NSAIDs, non-steroidal anti-inflammatory drugs; TNFi, TNF inhibitors; GC, glucocorticosteroids; (a) and (b) had different means according to Duncan’s multiple comparison test (age and period of exposure) or (c) Dunnet’s test at an overall level of significance of 5%

ISSN: 2523-3106